Molecular Targeting for Epidermal Growth Factor Receptor Expressed on Breast Cancer Cells by Human Fusion Protein - PubMed (original) (raw)
. 1997 Dec 25;4(4):253-255.
doi: 10.1007/BF02966516.
Affiliations
- PMID: 11091609
- DOI: 10.1007/BF02966516
Molecular Targeting for Epidermal Growth Factor Receptor Expressed on Breast Cancer Cells by Human Fusion Protein
M Ueda et al. Breast Cancer. 1997.
Abstract
Recombinant human ribonuclease 1 (RNase 1) was chemically linked to recombinant human epidermal growth factor (EGF). The cytotoxicity of this conjugate was assayed using MTT assay. The EGF-RNase conjugate showed dose-dependent cytotoxicity against breast and squamous cell carcinomas overexpressing the EGF receptor (EGFR). The cytotoxicity of the conjugate correlated positively with the level of EGFR expression by each cell line. These results suggest that the EGF-RNase conjugate is a more effective anticancer agent with less immunogenicity and toxicity than conventional chimeric breast cancer toxins.
Similar articles
- Epidermal growth factor receptor-dependent cytotoxic effect by an EGF-ribonuclease conjugate on human cancer cell lines--a trial for less immunogenic chimeric toxin.
Jinno H, Ueda M, Ozawa S, Kikuchi K, Ikeda T, Enomoto K, Kitajima M. Jinno H, et al. Cancer Chemother Pharmacol. 1996;38(4):303-8. doi: 10.1007/s002800050487. Cancer Chemother Pharmacol. 1996. PMID: 8674151 - Epidermal growth factor receptor-dependent cytotoxicity for human squamous carcinoma cell lines of a conjugate composed of human EGF and RNase 1.
Jinno H, Ueda M, Ozawa S, Ikeda T, Enomoto K, Psarras K, Kitajima M, Yamada H, Seno M. Jinno H, et al. Life Sci. 1996;58(21):1901-8. doi: 10.1016/0024-3205(96)00174-9. Life Sci. 1996. PMID: 8637416 - The cytotoxicity of a conjugate composed of human epidermal growth factor and eosinophil cationic protein.
Jinno H, Ueda M, Ozawa S, Ikeda T, Kitajima M, Maeda T, Seno M. Jinno H, et al. Anticancer Res. 2002 Nov-Dec;22(6C):4141-5. Anticancer Res. 2002. PMID: 12553045 - Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy.
Yang XD, Jia XC, Corvalan JR, Wang P, Davis CG. Yang XD, et al. Crit Rev Oncol Hematol. 2001 Apr;38(1):17-23. doi: 10.1016/s1040-8428(00)00134-7. Crit Rev Oncol Hematol. 2001. PMID: 11255078 Review. - The ErbB/HER family of protein-tyrosine kinases and cancer.
Roskoski R Jr. Roskoski R Jr. Pharmacol Res. 2014 Jan;79:34-74. doi: 10.1016/j.phrs.2013.11.002. Epub 2013 Nov 20. Pharmacol Res. 2014. PMID: 24269963 Review.
Cited by
- In vitro and in vivo studies of a VEGF121/rGelonin chimeric fusion toxin targeting the neovasculature of solid tumors.
Veenendaal LM, Jin H, Ran S, Cheung L, Navone N, Marks JW, Waltenberger J, Thorpe P, Rosenblum MG. Veenendaal LM, et al. Proc Natl Acad Sci U S A. 2002 Jun 11;99(12):7866-71. doi: 10.1073/pnas.122157899. Proc Natl Acad Sci U S A. 2002. PMID: 12060733 Free PMC article. - Targeting the EGF receptor for ovarian cancer therapy.
Zeineldin R, Muller CY, Stack MS, Hudson LG. Zeineldin R, et al. J Oncol. 2010;2010:414676. doi: 10.1155/2010/414676. Epub 2009 Dec 28. J Oncol. 2010. PMID: 20066160 Free PMC article.
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous